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Blood plasmacytoid dendritic cells (pDCs) contribute to both innate and adaptive immune responses by secreting high levels of IFN-α
following acute bacterial and viral infections and indirectly by augmenting cell-mediated immunity. Cross-sectional studies have shown that the
number of circulating pDCs in HIV patients, compared to that in uninfected individuals, is reduced. However, since the time of infection is usually
unknown in HIV-infected patients, pDC–virus interactions that occur immediately after virus exposure are poorly understood. The current study
investigated pDC dynamics during acute and chronic infections of macaques with either SIVmac239 or the pathogenic SIV–HIV chimera, SHIV-
89.6P, as models for HIV infection. In three rhesus and three pig-tailed macaques infected intravenously with SIVmac239, the percentages of
pDCs in blood declined 2- to 6-fold during the first 6 weeks after infection and remained depressed throughout the disease course. Surprisingly, no
consistent, comparable decline in peripheral blood pDCs was observed in six macaques infected with SHIV-89.6P. In this latter group, percentages
of pDCs did not correlate with CD4+ T cells, but there was an inverse relationship with viral load. In addition, when compared to naïve controls,
the percentages of pDCs were reduced in spleens and peripheral lymph nodes of SIVmac239- but not SHIV-89.6P-infected animals that had
progressed to AIDS. Proviral DNAwas detected during the acute phase in pDCs isolated from macaques infected with either virus. These results
imply that, even though macaque pDCs can be infected by both SIVmac239 and SHIV-89.6P, the subsequent effects on in vivo pathogenesis
differ. The underlying mechanism(s) for these differences is unclear, but the selection of SIV or SHIV as a challenge virus might influence the
outcome of some studies, such as those evaluating vaccines or the therapeutic efficacy of drugs.
© 2007 Elsevier Inc. All rights reserved.Keywords: Plasmacytoid dendritic cells; SIVmac239; SHIV-89.6P; Macaque; PathogenesisIntroduction
Plasmacytoid dendritic cells (pDCs) are key effectors in
innate immunity, are among the first responders to bacterial or
viral infections, and produce more interferon (IFN)-α than any
other cell type (Colonna et al., 2004; Siegal et al., 1999).
Phenotypically, human pDCs are characterized as CD123+HLA-
DR+ lineage-negative (Lin−, CD3−CD14−CD16−CD20−
CD56−) cells and are distinct from the other major blood DC
type, myeloid DCs (mDCs), which express CD11c, but not
CD123. In response to Toll-like receptor 9 (TLR9) recognition
of unmethylated CpG motifs found in the genomes of bacteria
and some DNA viruses, pDCs become activated, undergo⁎ Corresponding author. Fax: +1 205 975 6788.
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doi:10.1016/j.virol.2007.03.055maturation, and secrete cytokines (Bauer et al., 2001; Del Corno
et al., 2005; Krug et al., 2001; Lund et al., 2003; Teleshova et al.,
2004, 2006). Based on their ability to activate pDCs, short
oligodeoxynucleotides containing CpG motifs have been used
as adjuvants in studies evaluating various vaccine candidates for
immunogenicity (Cafaro et al., 2001; Jones et al., 1999). Since
pDCs also express TLR7 and TLR8, that recognize single-
stranded RNA, these cells are activated following infection by
RNA viruses, including the human immunodeficiency virus
(HIV) (Beignon et al., 2005; Diebold et al., 2004; Lund et al.,
2004).
Innate and adaptive immune systems are linked indirectly by
pDCs, which produce cytokines that augment NK-cell and virus-
specific cytotoxic T-cell responses and induce the generation of
T-helper 1 (Th1) and T-regulatory cells (Fonteneau et al., 2003;
Gerosa et al., 2005; Megjugorac et al., 2004; Moseman et al.,
357R.K. Reeves, P.N. Fultz / Virology 365 (2007) 356–3682004; Teleshova et al., 2004). During viral and bacterial
infections, pDCs migrate to inflamed lymph nodes through
high endothelial venules (Cella et al., 1999; Yoneyama et al.,
2004). Furthermore, pDCs are known to accumulate in nasal and
vaginal mucosae following respiratory syncytial and herpes
simplex type 2 virus infections, respectively, and can potentiate
inflammatory and autoimmune diseases, such as allergic rhinitis
and systemic lupus erythematosus, by producing large amounts
of IFN-α and other inflammatory cytokines and by aggregating
in lesion sites (Farkas et al., 2001; Gill et al., 2005; Jahnsen et al.,
2000; Lund et al., 2006).
In vitro exposure of pDCs either to infectious or inactivated
HIVor to purified gp120 results in production of high levels of
IFN-α and upregulation of activation markers, such as CD40,
CD83, and CD86 (Del Corno et al., 2005; Ferbas et al., 1994;
Fong et al., 2002; Fonteneau et al., 2004; Herbeuval et al., 2005;
Schmidt et al., 2005; Yonezawa et al., 2003). Circulating pDCs
in HIV-infected patients also express higher levels of CD86 than
do these cells in uninfected individuals (Barron et al., 2003).
However, in the blood of HIV-infected patients, percentages and
absolute numbers of pDCs and pDC-dependent IFN-α produc-
tion by peripheral blood mononuclear cells (PBMCs) were
reduced (Chehimi et al., 2002; Feldman et al., 2001; Pacanowski
et al., 2001; Soumelis et al., 2001). In general, these decreases
correlated positively with CD4+ T cell numbers and inversely
with viral loads (Barron et al., 2003; Donaghy et al., 2001; Finke
et al., 2004; Pacanowski et al., 2001; Schmidt et al., 2006;
Soumelis et al., 2001). Of interest, pDCs isolated from patients
not only were infected with HIV, as shown by virus production
during co-culture of pDCs with CD4+ cells or detection by
immunohistochemistry or PCR amplification of proviral DNA,
but also were impaired in their ability to stimulate allogeneic T
cells, suggesting that HIV infection of pDCs might contribute to
the observed loss of these cells (Donaghy et al., 2003; Fong
et al., 2002; Schmidt et al., 2004). That HIV can infect human
pDCs is supported by in vitro studies demonstrating that human
pDCs can be productively infected by both CCR5 (R5)- and
CXCR4 (X4)-using HIV isolates and, subsequently, can form
syncytium (Lore et al., 2005; Patterson et al., 2001; Schmidt
et al., 2004; Schmitt et al., 2006; Smed-Sorensen et al., 2005).
However, when patients were placed on highly active anti-
retroviral therapy (HAART), which can restore CD4+ T cell
numbers in blood and lead to undetectable plasma viremia, there
was only a partial restoration of pDC numbers and IFN-α
production (Chehimi et al., 2002; Finke et al., 2004; Schmidt
et al., 2006; Zhang et al., 2006). Consistent with HIV infections,
pDCs are reduced in other viral infections, including hepatitis B
virus (Duan et al., 2004), hepatitis C virus (Goutagny et al.,
2004), SARS coronavirus (Zhang et al., 2005), and human T-
lymphotropic virus (Hishizawa et al., 2004). Furthermore, in
severe hemorrhagic fevers resulting from dengue virus infection
of children, decreased percentages and numbers of pDCs are
associated with high levels of viremia (Pichyangkul et al., 2003).
The exact mechanisms responsible for the loss of this cell type in
association with these viruses are unknown.
Most studies have characterized HIV infection of human
pDCs ex vivo; however, a cell type phenotypically and func-tionally equivalent to human pDCs has been identified in rhesus
macaques (Macaca mulatta), thus making the simian immuno-
deficiency virus (SIV)-macaque model available for use when
asking questions about pDCs and lentivirus infections (Chung
et al., 2005; Coates et al., 2003). Although considerable research
has focused on understanding the dynamics of pDCs during HIV
infection, much is still unclear, particularly specific interactions
between HIV and pDCs during acute disease and whether any
alterations in phenotype or numbers of pDCs that are detected in
blood also occur in other tissues. Therefore, in this study we
phenotypically characterized cellular counterparts of human
pDCs in both rhesus and pig-tailed (Macaca nemestrina)
macaques and assessed the effects on pDCs of acute and chronic
lentivirus infection with an R5 virus, SIVmac239, and an X4
SIV/HIV chimera, SHIV-89.6P, both of which cause an AIDS-
like disease in these macaque species.
Results
Enumeration and phenotypic characterization of macaque
pDCs
Human pDCs in blood are phenotypically characterized as
CD123+HLA-DR+Lin− and represent less than 1% of all
mononuclear cells (Barron et al., 2003; Pacanowski et al.,
2001). To identify cells of the same phenotype in pig-tailed and
rhesus macaques, human antibodies cross-reactive for antigens
of both species were used. Macaque pDCs in blood (Fig. 1A,
gate R4) were identified by flow cytometry and were
distinguishable from CD123++HLA-DR− basophils (Fig. 1A,
gate R3). Macaque pDCs were also distinct from the other
major blood dendritic cell subset, mDCs, which are CD123lo/−
HLA-DR+Lin− (Fig. 1A, gate R5) and express high levels of the
cell-surface integrin, CD11c (data not shown). Thus, the
defining phenotypes of human and macaque pDCs appear to
be identical. Because human pDCs also express high levels of
CD4 (Patterson et al., 2001), we analyzed macaque pDCs for
expression of CD4 and the HIV/SIV/SHIV major coreceptors,
CCR5 and CXCR4 (Fig. 1B). Although one pig-tailed macaque
was an outlier with fewer (11.5%) pDCs that expressed CD4
than all other animals, in general, pig-tailed and rhesus macaque
pDCs had comparable levels of CD4 on the cell surface (Table
1). In both species expression of CCR5 suggested a high cell
surface density, as indicated by the MFI, with CCR5 present on
90% to 100% of pDCs. In contrast, the ranges of CXCR4+pDCs
were broad, and the median MFI for CXCR4 expression was
approximately tenfold lower than that for CCR5 (p<0.0001).
A comparison of the proportions of pDCs in whole blood and
PBMC samples from pig-tailed (n=22) and rhesus (n=11)
macaques revealed that the median percentage of pDCs in pig-
tailed macaques (0.198%) was significantly higher (p<0.001,
Mann–Whitney U test) than that in rhesus macaques (0.118%)
(Fig. 2). However, the absolute numbers of pDCs/ml of
peripheral blood in pig-tailed (median, 5794; range, 3772 to
16,799) and rhesus (median, 6697; range, 5124 to 15,924)
macaques were comparable. This discrepancy might be related,
in part, to the observation that normal, uninfected rhesus
Fig. 1. Phenotypic analysis of macaque pDCs. (A) Using flow cytometry, pDCs (R4 gate) were identified among blood mononuclear cells as those cells expressing no
lineage (Lin) markers (CD3, CD14, CD16, and CD20), but staining positive for HLA-DR and CD123. Differential expression of HLA-DR and Lin markers also
identified CD123++ basophils (R3 gate) and CD123lo/−HLA-DR+Lin− mDCs (R5 gate). (B) Expressions of CD4, CCR5, and CXCR4 on macaque pDCs in blood are
shown in representative histograms.
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peripheral blood lymphocytes than pig-tailed macaques; median
values, as determined from complete blood cell counts and
differentials, were 4207 and 2982 for rhesus (n=7) and pig-
tailed (n=15) macaques, respectively.
Dynamics of pDCs in blood of SIV/SHIV-infected macaques
To evaluate changes in the percentages and numbers of
circulating pDCs during acute and chronic lentivirus infections,
we performed a retrospective longitudinal analysis using
cryopreserved PBMC from three rhesus and three pig-tailed
macaques infected with SIVmac239 and six pig-tailed macaques
infected with SHIV-89.6P (Fig. 3A). In the three rhesusTable 1
Expression of SIV/SHIV receptors on macaque pDCs
Receptor No. a MFI b Percent positive c
Rhesus
CD4 7 112 (70.5–236) 97.7 (79.1–100)
CCR5 8 427 (103–629) 98.5 (89.1–100)
CXCR4 8 53.7 (35.6–99.4) 53.6 (25.5–73.9)
Pig-tailed
CD4 7 134 (25.0–289) 82.8 (11.5–98.8)
CCR5 11 416 (141–1290) 97.6 (91.9–100)
CXCR4 10 72.7 (14.1–91.6) 48.9 (19.6–65.0)
a Number of macaques whose pDCs were evaluated for surface expression of
the indicated receptor.
b Results are provided as medians (range) of the MFIs, mean fluorescence
intensities, of each receptor expressed on CD123++HLA−DR+Lin-pDCs (Fig.
1A, gate R4) in an expanded lymphocyte and monocyte gate (Fig. 1A, gate R1).
c Percentages of pDCs (Fig. 1A, gate R4) that express the indicated receptor.macaques the percentages of pDCs in PBMC declined rapidly
during the first weeks post-infection, with the mean reaching a
low of 0.028% at 6 weeks compared to 0.237% on day 0.
Furthermore, no appreciable recovery of pDCs was observed
during the chronic phase of infection. Similarly, the percentages
of pDCs declined during acute SIVmac239 infection of the pig-
tailed macaques, from a mean of 0.241% on day 0 to 0.076% by
week 4, with minimal to no recovery of pDCs observed during
chronic infection. A possible exception was noted for macaque
99P041: an increase in the percentages of pDCs, which persisted
at least 24 weeks before declining, was noted initially at 6 weeks
after infection; however, the increase never reached 50% of theFig. 2. Frequencies of pDCs in macaque whole blood or isolated PMBC.
Percentages of circulating CD123++HLA-DR+Lin− pDCs in normal pig-tailed
(n=26) and rhesus (n=11) macaques were determined by multi-color flow
cytometry. To enlarge the sample size, fresh whole blood and cryopreserved
PBMC were analyzed and results were combined after determining that they
were comparable. The horizontal lines indicate medians.
Fig. 3. Changes in percentages of pDCs and viremia in macaques infected with SIVmac239 or SHIV-89.6P. (A) Percentages of pDCs in cryopreserved PBMC were
determined by flow cytometry. Fewer data points are present at later times because some animals had been euthanized due to terminal disease. Trend lines were
generated from the means of percentages of pDCs for each week from weeks 0 to 6, and then from the means of all values for periods from 7 to 12, 12 to 52, or greater
than 52 weeks. Note differences in scales on the y-axes. (B) Plasma viral loads during the acute phase of infection were quantified by real-time PCR. Curves represent
the mean RNA copy numbers for each time point. Rh, rhesus macaques; Pt, pig-tailed macaques.
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mean percentages of pDCs from the six SHIV-89.6P-infected
macaques declined from 0.291% on day 0 to 0.128% at 2 weeks
post-infection, a reduction of approximately 56%. The frequen-
cies of pDCs then returned to normal levels by week 4 and
showed only a slight downward trend during late-stage disease.
The absolute number of pDCs also declined early after
SIVmac239 infection and remained lower than day-0 values
throughout the 9- to 81-week chronic infection period (Table 2).
Five of the six SIVmac239-infected animals experienced
decreases in the total number of pDCs at 1 week post-infection,
the exception being macaque N7K, which had a transient
increase before exhibiting a decline in numbers of pDCs.
Because of limited availability of cryopreserved PBMC
obtained during the first 8 weeks from the SHIV-89.6P-infected
animals, definitive conclusions cannot be made; however, there
appeared to be an overall loss in absolute numbers of pDCs, but
these numbers fluctuated more than those in the SIVmac239-infected animals (Table 2). Overall, relative to day-0 values, the
absolute numbers of circulating pDCs in the SIVmac239-
infected animals during the chronic phase were lower than those
in the SHIV-89.6P-infected animals. Most of the latter group
had severe lymphopenia that developed during chronic
infection (data not shown), which probably accounted for a
portion of the observed decreases in pDC numbers.
Association of viral load with loss of pDCs
Viral loads, measured as virion RNA copies/ml of plasma,
generally peaked at about 2 weeks for most animals; maximum
titers for the SHIV-89.6P-infected macaques were at least
fivefold higher than those for the SIVmac239-infected animals
(geometric means: SIVmac239-infected rhesus macaques,
1.3×106 copies/ml; SIVmac239-infected pig-tailed macaques,
9.1×106 copies/ml; and SHIV-89.6P-infected pig-tailed maca-
ques, 5.0×107 copies/ml) (Fig. 3B). Peak viremia also
Table 2
Changes in absolute numbers of pDCs in macaque peripheral blood after SIV/
SHIV infection
Macaque Weeks after infection
0 1 2 3–8 9–81
SIVmac239 – Rh a
K7K 6789 b 5319 3586 943±144 c 2247±864
N2V 5124 1174 1263 885±20 1811±630
N7K 6605 10,312 555 1824±241 1887±1314
SIVmac239 – Pt
AD7C 5179 1979 NAd 910±228 675±233
AK93 9722 3480 NA 1296±614 1626±507
99P041 12,895 6158 1835 3990 e 4833±747
SHIV-89.6P – Pt
95P001 7270 2968 NA 2421e 1904±620
95P002 3772 3774 NA NA 4990±1649
95P003 5388 15,814 1042 3473±2294 3060±1412
98P012 10,228 NA 4006 4860±3885 7832±3316
AP1D 6799 NA 905 3252±1073 2552±2469
AP1E 13,933 NA 1834 5237±1675 2901±1205
a Individual animals infected with the indicated virus. Rh, rhesus macaques;
Pt, pig-tailed macaques.
b The absolute number of pDCs was calculated using the percentages of pDCs
in PBMC and the total number of lymphocytes and monocytes obtained from
CBCs and differentials. Numbers are pDCs/ml of blood.
c Values are the mean number±one standard deviation of pDCs/ml for the
indicated period.
d NA, not analyzed due to lack of cell samples.
e Only one PBMC sample was analyzed from this time period.
Fig. 4. Relationship of percentages of pDCs and viral loads during infection of
macaques with SIVmac239 or SHIV-89.6P. (A) Values were obtained from three
rhesus and three pig-tailed macaques infected with SIVmac239 for 1 to
77 weeks and include four to seven time points for individual animals. Open
circles are values for rhesus macaques and closed circles are those for pig-tailed
macaques (Spearman's correlation). (B) Values were obtained from six pig-
tailed macaques infected with SHIV-89.6P for 1 to 52 weeks and include two to
six time points for individual animals.
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infected rhesus and pig-tailed macaques and the transient loss of
pDCs observed at 2 weeks after infection in the SHIV-89.6-
infected pig-tailed macaques. Although the relationship
between viral loads and percentages of pDCs in SIVmac239-
infected macaques was not statistically significant (Fig. 4A), it
is possible that the persistently low percentages of pDCs in
these animals compromised the accuracy of a correlative test.
However, there was an inverse correlation between viral loads
and percentages of pDCs in SHIV-89.6P-infected animals (Fig.
4B). When the relationships of absolute numbers of pDCs and
viral loads were evaluated, the results were similar (data not
shown).
To determine whether macaque pDCs were infected in vivo,
these cells were purified to 98.2% homogeneity using
adherence, Dynabead, and cell sorting procedures, and then
DNA was isolated and tested by PCR for amplification of a
region of the gag gene. During the first 12 weeks after infection,
all DNA samples isolated from pDCs from SIVmac239-infected
macaques were positive for provirus or cDNA (Table 3). For
example, provirus was amplified from genomic DNA equiva-
lent to 50 pDCS isolated from macaque N7K at 4 weeks after
infection, indicating that at least one in 50 cells was infected
with SIVmac239. However, provirus was not detected in
genomic DNA equivalent to 4300 pDCs that were isolated from
this same animal at 73 weeks. In the SHIV-89.6P-infected
macaques, two of three different pDC DNA samples obtained
during the first 12 weeks of infection were positive for provirus.Although DNA from pDCs from only two animals (one each
from a SIVmac239- and a SHIV-89.6P-infected macaque) at
late times of infection was analyzed, the results suggest not only
that more pDCs were infected during the acute rather than the
chronic phase but also that during the acute phase, the number
of infected pDCs was lower in SHIV-89.6P-compared to
SIVmac239-infected animals. There appeared to be no associa-
tion, however, between the apparent number of infected pDCs
and plasma viral loads.
Relationship of CD4+ T cells to pDCs
Both pDCs and CD4+ T cells in blood decline during
SIVmac239 infection of macaques, suggesting that the
decreases in both cell types might be related. However, no
correlation was found between the percentages of CD4+ cells
and pDCs in the SIVmac239-infected animals (Fig. 5A). As
reported previously by others (Karlsson et al., 1998; Reimann et
al., 1996), we found that peripheral blood CD4+ T cells rapidly
declined during acute SHIV-89.6P infection and, in most
animals, remained low thereafter (Fig. 5B). Although the onset
of loss of circulating CD4+ T cells coincided with the transient
loss of pDCs during acute SHIV-89.6P infections, numbers of
CD4+ Tcells were persistently low and rarely increased after the
acute stage; therefore, it was impossible to determine whether
Table 3
Amplification of proviral DNA from purified macaque pDCs
Animal Weeks a No. pDCs b PCR c G. eq. d Copies/ml e
SIVmac239
N2V 2 7.0×104 3/3 <120 1.7×105
4 5.5×103 2/3 ≤230 8.4×104
12 1.6×104 2/3 ≤670 2.6×105
N7K 4 3.3×103 3/3 <50 8.4×105
73 1.3×104 0/2 >4300 1.3×105
SHIV-89.6P
95P003 6 1.8×103 0/2 >580 9.6×104
8 2.8×104 2/3 ≤1200 2.4×105
62 1.7×103 0/2 >570 ND f
98P012 6 8.0×103 2/3 ≤330 1.0×103
Uninfected
98P058 NAg 8.7×103 0/2 >730 NAg
a Weeks after virus infection.
b All pDCs recovered from each PBMC sample after enrichment and
purification by live-cell sorting were used to isolate DNA for PCR. Purification
of pDCs from PBMC was done by first removing adherent cells, followed by
Dynabead depletion of Lin+ cells from the nonadherent fraction; the remaining
cells were sorted to obtain a population that contained, on average, 98.2%
CD123++ HLA-DR+Lin−pDCs.
c Positive PCR amplifications of a 359-bp fragment of gag are shown as a
fraction of total PCRs using a given sample. PCRs were performed with DNA
from different numbers of pDCs.
d Minimum number of pDC genome equivalents required for a positive PCR.
e Number of viral RNA copies/ml of plasma.
f Not done.
g Not applicable.
Fig. 5. Relationship of pDCs to CD4+ T cells. (A) Percentages of CD4+ T cells
and pDCs in PBMC were obtained from weeks 1 to 81 during SIVmac239
infection. Values for rhesus and pig-tailed macaques are as in Fig. 4A above. (B)
Percentages of CD4+ T cells during acute SHIV-89.6P infection of pig-tailed
macaques were determined using cryopreserved PBMC. The trend line is based
on the means of the percentages of CD4+ T cells for each week from weeks 0 to
6, and then on all means for percentages obtained during the periods from 7 to
12, 13 to 52, and 52 to 81 weeks. Each symbol represents the same animal as that
indicated in Fig. 3A, bottom panel.
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CD4+ T cells and pDCs.
Distribution of pDCs in lymphoid tissues
Since pDCs in humans, mice, and, recently, in rhesus
macaques (Cella et al., 1999; Coates et al., 2003; Teleshova et
al., 2006; Yoneyama et al., 2004) were shown to migrate to
secondary lymphoid tissues, we determined the proportion of
pDCs in different lymphoid tissues of naïve pig-tailedmacaques.
Flow cytometric analysis was performed on single-cell suspen-
sions prepared from PLN and MLN as well as spleen tissues
taken from animals at necropsy. Percentages of pDCs in tissues
from naïve pig-tailed macaques were compared to those of pDCs
in peripheral blood (discussed above); similar percentages of
pDCs in the total mononuclear cell population were found in
spleen tissue, but values were significantly higher in PLN
(p=0.04) and lower in MLN (p<0.0001) (data not shown).
Additionally, the proportions of pDCs in tissues from naïve
macaques were compared to those in tissues from pig-tailed
macaques that were infected with either SIVmac239 or SHIV-
89.6P and were at end-stage disease (Fig. 6). Even though the
median percentage of pDCs in spleens of SHIV-89.6P-infected
animals was higher than that of naïve animals (0.354% and
0.158%, respectively), percentages of pDCs in spleens and PLN
from naïve and SHIV-89.6P-infected macaques were not sta-
tistically different. In contrast, spleens and PLN from
SIVmac239-infected animals contained significantly lower per-centages of pDCs than those in both naïve and SHIV-89.6P-
infected animals. There were no differences in the percentages of
pDCs in MLN from any group.
Activation of pDCs
In general, pDCs in human blood are phenotypically
immature cells. To determine whether this is true in macaques,
multi-parametric flow cytometry was used to examine surface
expression of the activation/maturation markers CD40 and
CD86 on circulating pDCs in six pig-tailed and eight rhesus
macaques. The mean percentages of pDCs that were positive for
both markers was less than 1%, with MFIs comparable to those
of background controls (Fig. 7A), strongly indicating that
circulating pDCs inmacaques also have an immature phenotype.
Since retroviruses appear to have an effect on pDCs, we
determined whether infectious viruses activated these cells in
vitro. Macaque CD123+HLA-DR+pDCs were enriched and
cultured without or with SIVmac239 or SHIV-89.6P and, as
indicators of activation, expression of cell surface CD86 and
secretion of IFN-α were assessed. In mock-infected cultures,
CD86 detection was characterized by a mean MFI of 154, while
cells in the two virus-infected cultures had MFIs approximately
threefold higher (547 and 583) (Fig. 7B). For comparison, pDCs
in blood that were analyzed ex vivo had a mean MFI of 8.76.
Fig. 6. Variability of percentages of pDCs in tissues from naïve and SIV- or SHIV-infected macaques. Percentages of pDCs in single-cell suspensions of spleens,
peripheral lymph nodes (PLN), and mesenteric lymph nodes (MLN) from naïve and SIVmac239- and SHIV-89.6P-infected pig-tailed macaques at necropsy were
determined by flow cytometry. Times after infection with SIVmac239 and SHIV-89.6P when the animals were euthanized ranged from 67 to 150 weeks and 28 to
211 weeks, respectively. Within a given tissue, whether there were significant differences between macaque groups in median percentages (horizontal lines within data
sets) of pDCs was assessed using the Mann–Whitney U test; p values are not shown for medians that were not significantly different (p> 0.05). Cell samples for all
tissues were not available from all animals.
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and infected pDC cultures contained similar IFN-α concentra-
tions, which were 30-fold greater than that in supernatants from
the mock-infected cultures (Fig. 7C). Compared to pDCs in
blood, the modest increase in CD86 expression in the mock-
infected cultures (MFI increased from approximately 9 to 154)
could be due, in part, to ligation of IL-3Rα (CD123) by anti-Fig. 7. Activation of macaque pDCs by infection with SIVmac239 and SHIV-
89.6P. (A) Representative histograms showing no expression of CD40 and
CD86 on pDCs in peripheral blood from a naïve macaque. (B) Upregulation of
CD86 on enriched macaque pDCs is reflected as an increase in MFI. (C)
Concentrations of IFN-α in culture supernatants of enriched macaque pDCs
were determined by ELISA. CD86 and IFN-αwere measured 48 h after addition
of the indicated virus (moi=0.2). Values are means and standard deviations of
three independent experiments.bodies during the sorting process and/or the addition of IL-3 to
the culture media as a growth supplement for pDCs. Cross-
linking of CD123 in the presence of both a primary mAb and
secondary anti-IgG antibodies can induce maturation of pDCs
and downregulate IFN-α expression (Fanning et al., 2006);
however, we used only a primary anti-CD123 antibody for pDC
enrichment. Furthermore, IL-3 in the medium would compete
with any antibodies for binding to CD123; therefore, it is
unlikely that antibody-mediated downregulation of IFN-αwas a
major factor in modulating IFN-α production after virus
infection. The above results clearly show that SIV/SHIV in-
fection of Lin− pDC-enriched cultures induced activation of
these cells.
Discussion
When the adaptive immune system is impaired or fails, as in
HIV-1 infections, host innate immune responses must play a
larger role in defending against invading pathogens and
controlling opportunistic infections and neoplasms than in
normal individuals. Much of what is known regarding HIV
pathogenesis and the development of efficacious vaccines is
derived from analyses of SIV infections of nonhuman primates.
Although both pig-tailed and rhesus macaques are considered
comparable for a variety of studies, minor differences, such as in
frequencies of some cell types in blood, are not uncommon. For
example, Ibegbu et al. (2001) found significantly higher
percentages and absolute numbers of NK cells in pig-tailed
macaques than in either rhesus macaques or sooty mangabeys
(Cercocebus atys). Limited information about pDCs in maca-
ques is available, and it is restricted to rhesus macaques (Coates
et al., 2003; Teleshova et al., 2004, 2006). We report here that (i)
cells phenotypically similar to human pDCs are present in both
pig-tailed and rhesus macaques, and (ii) the frequency of
circulating pDCs in pig-tailed macaques is similar to, while the
frequency in rhesus macaques is lower than, that in humans
(Chehimi et al., 2002; Duan et al., 2004).
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rhesus and pig-tailed macaques with the same SIV or SHIV
strains are equivalent (Batten et al., 2006; Fultz et al., 2001,
2003; Reimann et al., 2005). In the present study, while the
effect of SIVmac239 on pDCs appeared to be comparable in
both macaque species, the effects of SIVmac239 and SHIV-
89.6P on CD4+ T cells were disparate and distinct. SIVmac239
caused a transient decline in the number of circulating CD4+ T
cells during acute infection, followed by a gradual decline
during the chronic phase. In contrast, SHIV-89.6P caused a loss
of >95% of all circulating CD4+ T cells within the first 2 to
4 weeks after infection, as reported by others (Reimann et al.,
1996). This difference is now known to be related to coreceptor
usage: most SIV strains use CCR5, while SHIV-89.6P uses
CXCR4 exclusively (Moore et al., 2004; Nishimura et al., 2004).
Although memory and naïve CD4+ T cells can express CXCR4,
the levels on naïve cells tend to be higher and, therefore, these
cells may be more susceptible targets for SHIV-89.6P infection
(Nishimura et al., 2005). In addition, the majority of SIV strains
infect memory CD4+ T cells, which are almost completely
depleted in gut and other lymphoid tissues during the first weeks
of SIV infections (Mattapallil et al., 2005), a result consistent
with events described in the gastrointestinal tracts of HIV-
infected humans (Brenchley et al., 2004). However, our data
demonstrated that, while the frequency of circulating pDCs
correlated with viral load, it was unrelated to CD4+ T cell
numbers. Similar studies of HIV patients have yielded
conflicting results: some reported a strong relationship between
pDC frequencies in blood and both viral load and CD4+ T cell
counts, while others found essentially no relationship (Chehimi
et al., 2002; Donaghy et al., 2001; Feldman et al., 2001; Schmidt
et al., 2006). One possible explanation for the discrepancy is that
these studies were a cross-sectional analysis of HIV patients at
various stages of disease; they did not include many subjects, if
any, who were acutely infected.
Since different primate lentiviruses target specific subsets of
CD4+ T cells, based on their use of coreceptors, it is tempting to
speculate that the effects of lentivirus pathogenesis on pDCs are
also, at least in part, coreceptor-dependent. Almost 100% of
macaque pDCs express levels of CCR5 that are logarithmically
higher than what is required for infection of memory CD4+ T
cells (Mattapallil et al., 2005), suggesting that pDCs might be
especially susceptible to infection by CCR5-using (R5) viruses
(Moore et al., 2004), which could explain the extensive decrease
in numbers of these cells during acute infection with
SIVmac239. This notion is supported by a recent report that
suggests infection of pDCs in vitro with R5 HIV isolates
produced higher proviral loads than comparably infected CD4+
T cells (Cameron et al., 2006). That the percentages of macaque
pDCs that express CXCR4 are highly variable and CXCR4 has a
lower surface density than CCR5 might explain the minor
impact of SHIV-89.6P infection on pDC frequencies in blood.
Independent of the route of transmission, R5 viruses tend to
predominate early in HIV-1 infection, and the emergence of
CXCR4-using (X4) viruses is associated with disease pro-
gression; however, at any given time viral quasispecies are likely
to be heterogeneous, comprised of both R5 and X4 variants(Moore et al., 2004). Thus, the effect of HIV on pDCs early in
infection might mimic what we observed during acute
SIVmac239 infection. However, while several groups have
shown that human pDCs express both CCR5 and CXCR4, little
data exist on the relationship of coreceptor expression levels and
virus infectivity (Lore et al., 2005; Schmitt et al., 2006; Smed-
Sorensen et al., 2005).
Even though we analyzed a limited number of purified pDC
populations, our results suggest that, after transmission of both
SIVmac239 and SHIV-89.6P, macaque pDCs were infected
early in the disease course and harbored proviral DNA. There
are no reports that positively identify SIV proviruses in
macaque pDCs, but several groups have shown not only that
human pDCs are infected in vivo but also that these cells can be
infected by HIV in vitro (Donaghy et al., 2003; Gurney et al.,
2004; Lore et al., 2005; Patterson et al., 2001; Smed-Sorensen et
al., 2005). Furthermore, human pDCs support more efficient
replication of an R5 virus (HIVBaL) than an X4 virus (HIVIIIB).
These differences between R5 and X4 HIV strains might
partially explain the diverse effects on macaque pDCs that we
observed during SIVmac239 and SHIV-89.6P infections. In
agreement with our results, R5 and X4 HIV isolates induced
production of similar amounts of IFN-α and upregulation of
CD86 on pDCs in vitro (Lore et al., 2005; Smed-Sorensen et al.,
2005; Yonezawa et al., 2003). Since both R5 and X4 viruses
stimulate pDCs equally, cell-mediated responses to both types
of SIV and SHIV strains most likely are similar and have little
impact on the disparate disease pathogenesis we observed.
Because virus stocks generally contain more noninfectious
virus particles than infectious virions, these noninfectious
particles also might activate pDCs and contribute to induction
of IFN-α, thus enhancing antiviral activity. In vitro experiments
have shown that infectious HIV is not required and that
recombinant gp120 alone is sufficient to activate human pDCs
(Del Corno et al., 2005; Fonteneau et al., 2004; Yonezawa et al.,
2003). Furthermore, Teleshova et al. (2004) showed that after
the addition of aldrithiol-2-inactivated SIV to cultures of
enriched macaque dendritic cells, CD80 and CD86 were
upregulated on CD123+ pDCs and IFN-α accumulated in
culture supernatants in a dose-dependent manner. A current goal
is to define more rigorously interactions between SIV and
macaque pDCs, but this objective has been hindered because
antibodies that are used for in vitro purification of pDCs from
human blood, such as the pDC-specific antigens BDCA-2 and
-4, crossreact poorly with the analogous nonhuman primate
antigens (Reeves and Fultz, unpublished data; Dzionek et al.,
2000). Thus, to facilitate characterization of macaque pDCs,
similar antibodies specific for macaque BDCA-2 and -4, or
other unidentified pDC-specific proteins, need to be generated.
Information regarding changes in pDC populations during
SIV and SHIV infections is limited. Teleshova et al. (2004)
reported that during chronic infections there were significantly
lower frequencies of pDCs in the blood of rhesus macaques
vaccinated with the attenuated SIVmac239Δnef strain and then
challenged with SIVmac239 compared to those in SHIV-162P-
infected macaques; however, neither of these frequencies were
statistically different from those in naïve controls. One caveat is
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infection, and only the percentages of pDCs among HLA-
DR+Lin− cells in the periphery, and not absolute numbers, were
determined. Prior vaccination of the SIVmac239-infected
animals also may have provided some protection against
substantial decreases in pDCs. After infection with SHIV-
162P, also an R5 virus, some animals can control viremia such
that either a viral set point that is lower (<1 log) than that
associated with SIVmac239 infection is established or virion
RNA becomes undetectable (Batten et al., 2006; Harouse et al.,
1999). Since our data suggest that pDC frequency is related to
viral load, low or undetectable levels of viremia could lead to
the re-emergence of pDCs in the peripheral blood of long-term
infected animals exhibiting no signs of disease progression.
Relative to this possibility, several studies have shown that in
HIV-infected patients whose viremia was suppressed due to
successful treatment with HAART, a partial restoration of
peripheral blood pDCs was observed (Chehimi et al., 2002;
Finke et al., 2004; Schmidt et al., 2006; Zhang et al., 2006).
In addition to HIV, and now SIVmac239, decreases in
circulating pDCs in a variety of viral (Duan et al., 2004;
Goutagny et al., 2004; Hishizawa et al., 2004; Zhang et al.,
2005), bacterial (Lichtner et al., 2006), and parasitic (Pichyang-
kul et al., 2004) infections, as well as in some non-microbial
pathologies (Baumgart et al., 2005; Blomberg et al., 2003), have
been demonstrated. Such peripheral alterations might be
explained by migration to and accumulation of pDCs at sites
of inflammation or in lymphoid organs (Cella et al., 1999;
Farkas et al., 2001; Gill et al., 2005; Jahnsen et al., 2000;
Pashenkov et al., 2002; Yoneyama et al., 2004); however, the
sustained decrease of pDCs in both blood and lymphoid tissues
at end-stage SIVmac239 infection makes this explanation
unlikely and suggests that infection and loss of pDCs occur
early and systemically, as is the case for CCR5+ memory CD4+
T cells (Mattapallil et al., 2005). In contrast, our findings of
elevated percentages of pDCs in spleens and mesenteric lymph
nodes of some SHIV-89.6P-infected macaques in end-stage
disease suggest there might be a continual influx and
accumulation of pDCs in lymphoid tissues during acute and/
or chronic infections with SHIV-89.6P that was not associated
with extensive loss of circulating pDCs. Since mucosal
infections represent the major route of HIV transmissions
worldwide, it would be of interest to determine whether pDCs
accumulate in the genital mucosa following rectal or vaginal
infection, as was shown for herpes simplex virus type 2
infection of mice (Lund et al., 2006).
In conclusion, our results using the SIV/SHIV macaque
models suggest that, in patients chronically infected with HIV,
loss of pDCs occurs primarily during acute infection and may be
linked to coreceptor usage by a virus and/or coreceptor
expression on pDCs. However, other factors, including
dysregulation of pDC development or direct killing by NK
cells, could affect the numbers of pDCs in blood and tissues.
Regardless of the mechanism(s) involved, loss of a functional
pDC population would have detrimental consequences on innate
immune functions. Impairment of the innate immune system, in
turn, would enhance acquisition of opportunistic infections andaffect immunization against pathogens, with or without targeting
pDCs, or development of therapeutic strategies (Becker, 2005;
Cafaro et al., 2001; Jones et al., 1999; Teleshova et al., 2004;
Verthelyi et al., 2003). Furthermore, the differences between
SIVmac239 and SHIV-89.6P infection of macaques that we
identified here suggest that, when using these models, the choice
of an appropriate challenge virus may be critical for the specific
hypothesis being tested.
Materials and methods
Animals and cell samples
Juvenile rhesus and pig-tailed macaques of both sexes were
used in this study. All of the SIV- and SHIV-infected animals
had been or at the time were in other unrelated pathogenesis
studies. Uninfected animals were used as normal blood donors.
Before collecting blood samples or inoculating virus, macaques
were anesthetized with an intramuscular injection of ketamine
HCl (10 mg/kg). Macaques were housed in isolation facilities at
the University of Alabama at Birmingham in accordance with
institutional and Animal Welfare Act guidelines.
Whole blood was collected from macaques and PBMC were
isolated from heparinized blood by density gradient centrifuga-
tion through lymphocyte separation medium (LSM, ICN
Biomedicals, Inc.). To evaluate changes in subsets of peripheral
blood cells, cryopreserved PBMCs, obtained during previous
studies from three rhesus and three pig-tailed macaques infected
with SIVmac239 and six pig-tailed macaques infected with the
SHIV-89.6P chimera were used. Cells collected up to 81 weeks
post-infection, or for a shorter time when an animal had
progressed to AIDS, were assessed. Lymphoid tissues were
evaluated using fresh or cryopreserved single-cell suspensions
of PLN and MLN and spleens taken at necropsy from
uninfected or infected animals in end-stage disease. Animals
from which tissue samples were available included: uninfected
(n=9); SHIV-89.6P-infected (n=10); and those infected with
SIVmac239 (n=5) or one of two SIVmac239 mutants,
SIVmac239Y>I (n=2) or SIVmac239ΔGY(S>P) (n=2). The
two SIVmac239 mutant strains were described previously
(Fultz et al., 2001; LaBranche et al., 1995). Since no significant
differences were observed among animals infected with either
of the two mutant or wild-type SIVmac239 strains with respect
to effects on pDCs, for the purposes of this study, the animals
were grouped and collectively referred to as being infected with
SIVmac239.
Flow cytometric analysis of ex vivo mononuclear cells
Three- and four-color flow cytometry were used to
enumerate percentages of various cell types and to characterize
phenotypically macaque pDCs in EDTA-treated whole blood,
PBMC, or single-cell suspensions of splenic and lymph node
tissues. CD123+ pDCs were identified within HLA-DR+Lin−
populations using: a FITC-conjugated antibody cocktail to Lin
markers CD3ε (SP34), CD14 (MϕP9), CD16 (3G8), and CD20
(2H7); PE-labeled anti-CD123 (7G3); and PerCp-labeled anti-
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maturation molecules was evaluated using one of the following
antibodies: anti-CD40 (5C3), anti-CD86 (2331), anti-CCR5
(2D7), or anti-CXCR4 (12G5), all of which were conjugated to
APC. CD4 expression on pDCs was evaluated by indirect
staining using biotin-conjugated anti-CD4 (SK3), and either
anti-biotin–APC (Miltenyi Biotec, Germany) or streptavidin–
APC. CD4+ T lymphocytes were identified using PE-labeled
anti-CD4 (SK3). Isotype-matched controls for each fluoro-
chrome were included in all experiments and were used to
calculate percentages of positive cells above background
fluorescence. For phenotyping pDCs, mononuclear cells were
gated based on forward-and-side-scatter characteristics. All
antibodies and reagents were purchased from BD Biosciences
Pharmingen (San Diego, CA), unless otherwise noted, and all
acquisitions were performed on a BD LSRII flow cytometer.
pDC enrichment, isolation, and activation
pDCs were enriched, first, by culturing whole PBMC from
naïve pig-tailed macaques for a minimum of 4 h in RPMI 1640
containing 15% FBS to deplete adherent cells and, second, by
depleting other Lin+ cells using Pan-IgG Dynabeads (Dynal
Biotech, Norway) coated with anti-CD3 (FN-18) (Biosource,
Camarillo, CA), anti-CD16 (3G8) and anti-CD20 (2H7) (both
from BD Biosciences). The remaining cell fraction was
incubated with anti-CD123-PE Ab; all CD123+ cells were
sorted and collected using a BD FACS Aria. For activation
experiments, aliquots of enriched cells were reanalyzed; greater
than 95% of cells were negative for Lin markers, 40 to 70%were
HLA-DR+pDCs, and the remaining cells were CD123+HLA-
DRdim/−Lin−, most likely basophils (Strunk et al., 2005; Toba
et al., 1999). Alternatively, for PCR experiments in which a
relatively pure pDC population was necessary, the enriched cell
fraction (97% Lin− cells) was stained with anti-CD123-PE and
anti-HLA-DR-PerCp or -FITC and only double-positive cells
were collected by sorting; these cells were 98.2% CD123+HLA-
DR+Lin− (mean, eight experiments). To avoid possible activa-
tion or induction of apoptosis by HLA-DR ligation (Nagy and
Mooney, 2003), cells enriched only for CD123 were assayed.
Approximately 2.5×104 cells were cultured in polystyrene tubes
in enriched medium (RPMI 1640 supplemented with 10% FBS,
10% normal monkey serum, and 20 ng of IL-3/ml) with either
SIVmac239 or SHIV-89.6P at a moi of 0.2. After 48 h, culture
supernatants were collected and the cells were washed and
reanalyzed by flow cytometry for CD86 (FITC) expression on
CD123+HLA-DR+ cells. As another measure of activation,
concentrations of IFN-α in the 48-h culture supernatants were
determined using a cross-reactive human IFN-α ELISA kit,
according to the manufacturer's (Biosource) protocol. The lower
limit of detection of IFN-α was 10 pg/ml.
Detection of provirus in pDCs
CD123++HLA-DR+Lin− pDCs were purified from the 97%
Lin− population by cell sorting, as described above, using
PBMC from SIVmac239- and SHIV-89.6P-infected macaquesat various stages of disease. Isolated cells were mixed with
uninfected CEMx174 cells (1:10 ratio, pDCs to CEMx174 cells)
to provide a source of carrier DNA. Proviral DNAwas amplified
by nested PCR as a 359-bp fragment of SIVmac239 gag (also
encoded by the chimeric SHIV-89.6P). The first-round gag
primers were: forward, 5′-CGCAGAAGAGAAAGTGAAA-
CAC-3′, and reverse, 5′-AAGCCGTCAGCATTTCTTC-3′
(spanning nucleotide positions 1319 to 2103). The second-
round gag primers were: forward, 5′-TGGTAACTATGTC-
CACCTGCC-3′, and reverse, 5′-TGCCTACTGGTATGGGG-
TTC-3′ (spanning nucleotide positions 1475 to 1833). DNA
isolated from SIVmac239-infected or uninfected CEMx174
cells served as positive and negative controls, respectively.
Viral load
Plasma virion RNAwas quantified (sensitivity, less than 100
copies/ml) for SIVmac239-infected (99P041, AK93, and
AD7C) and SHIV-89.6P-infected pig-tailed macaques
(98P012, AP1D, and AP1E) at the Quantitative Molecular
Diagnostics Core of the AIDS Vaccine Program, SAIC
Frederick, NCI (Frederick, MD), as described (Lifson et al.,
2001). Viral load data for SIVmac239-infected rhesus (N2V,
K7K, and N7K) and SHIV-89.6P-infected pig-tailed macaques
(95P001, 95P002, and 95P003) were reported previously (Fultz
et al., 2001, 2003).
Statistical analyses
Comparisons of results were done using Spearman's
correlation or, when data from two or more groups were
analyzed, the Mann–Whitney U test. Differences were
considered significant if p values were less than 0.5. All
analyses were performed using InStat 2.0 software (GraphPad,
San Diego, CA).
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